STOCK TITAN

Adamis Pharmaceuticals Corp - ADMP STOCK NEWS

Welcome to our dedicated news page for Adamis Pharmaceuticals (Ticker: ADMP), a resource for investors and traders seeking the latest updates and insights on Adamis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adamis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adamis Pharmaceuticals's position in the market.

Rhea-AI Summary
Adamis Pharmaceuticals Corporation changes its name to DMK Pharmaceuticals Corporation and will begin trading under the ticker symbol 'DMK' on September 8, 2023. The company's new strategic focus is on advancing small molecules for the treatment of substance use disorders. DPI-125, the company's lead clinical stage compound, is expected to have several significant milestones by the end of 2024. These include a transdermal delivery system, safety study results compared to fentanyl, pharmacokinetic study results in humans, and abuse liability study results compared to current treatments for OUD and pain relief.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces Q2 2023 financial results and recent corporate developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation has closed its public offering of 5,930,000 units, each consisting of one share of common stock and one warrant. The units were sold at a public offering price of $1.35 per unit, resulting in gross proceeds of approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
offering
Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces pricing of public offering at $1.35 per unit, expected to raise approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.67%
Tags
offering
-
Rhea-AI Summary
Adamis Pharmaceuticals commits to funding an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Dr. Albert Dahan, an expert on opioid-induced respiratory depression. The collaboration aims to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg intranasal naloxone in reversing fentanyl-induced respiratory depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
none
Rhea-AI Summary
Adamis Pharmaceuticals CEO participates in White House Roundtable on Opioid Crisis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
none
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced the completion of its merger with DMK Pharmaceuticals Corporation. The combined company will focus on increasing sales of Adamis' commercial products and advancing DMK's lead clinical stage compound, DPI-125, for the treatment of opioid use disorder (OUD). Ebrahim Versi, CEO of DMK, has been named CEO of Adamis and Chairman of the Board of Directors. The global opioid market in 2021 was reported to be greater than $22 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.2%
Tags
acquisition
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Adamis Pharmaceuticals Corp

Nasdaq:ADMP

ADMP Rankings

ADMP Stock Data

7.25M
9.14M
7.81%
16.59%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ADMP

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a